Stryker shares fell $26.70 (-8.8%) on September 8 after CFO Preston Wells said a manufacturing issue in the Peripheral Vascular unit is continuing into Q4, contradicting prior guidance that it would be resolved by end of Q3. The drop erased over $10 billion in market cap. Hagens Berman has opened an investigation into whether Stryker violated securities laws.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
